[go: up one dir, main page]

AU2003222513A1 - Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure - Google Patents

Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure

Info

Publication number
AU2003222513A1
AU2003222513A1 AU2003222513A AU2003222513A AU2003222513A1 AU 2003222513 A1 AU2003222513 A1 AU 2003222513A1 AU 2003222513 A AU2003222513 A AU 2003222513A AU 2003222513 A AU2003222513 A AU 2003222513A AU 2003222513 A1 AU2003222513 A1 AU 2003222513A1
Authority
AU
Australia
Prior art keywords
cardiomyopathy
preventing
heart failure
vascular disease
treating vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003222513A
Inventor
Richard John Baker
Garth James Smith Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protemix Corp Ltd
Original Assignee
Protemix Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protemix Corp Ltd filed Critical Protemix Corp Ltd
Publication of AU2003222513A1 publication Critical patent/AU2003222513A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003222513A 2002-03-08 2003-03-10 Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure Abandoned AU2003222513A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ51772202 2002-03-08
NZ517722 2002-03-08
PCT/NZ2003/000043 WO2003075910A1 (en) 2002-03-08 2003-03-10 Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure

Publications (1)

Publication Number Publication Date
AU2003222513A1 true AU2003222513A1 (en) 2003-09-22

Family

ID=27800845

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003222513A Abandoned AU2003222513A1 (en) 2002-03-08 2003-03-10 Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure

Country Status (2)

Country Link
AU (1) AU2003222513A1 (en)
WO (1) WO2003075910A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198334B2 (en) * 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
EP1115389B1 (en) 1998-09-25 2014-03-12 PhilERA New Zealand Limited Fructosamine oxidase: antagonists and inhibitors
CA2467689C (en) * 2001-12-06 2013-10-01 Fibrogen, Inc. Stabilization of hypoxia inducible factor (hif) alpha using inhibitors of hif prolyl hydroxylase
WO2003077901A1 (en) * 2002-03-08 2003-09-25 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
EP1539129A4 (en) 2002-08-20 2006-03-08 Protemix Corp Ltd Dosage forms and related therapies
AU2003263948A1 (en) * 2002-08-22 2004-03-11 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
MXPA05012619A (en) * 2003-05-21 2006-02-08 Univ Texas Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure.
PT1778618E (en) 2004-07-19 2014-03-04 Philera New Zealand Ltd Synthesis of triethylenetetramines
WO2006104401A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
WO2006132583A1 (en) * 2005-06-07 2006-12-14 Innate Pharmaceuticals Ab Method and means for preventing and inhibiting respiratory disease, atherosclerosis and osteoporosis caused by chlamydia pneumoniae infection
MX2009010407A (en) 2007-03-28 2009-12-01 Apotex Technologies Inc Fluorinated derivatives of deferiprone.
WO2009129592A1 (en) 2008-04-25 2009-10-29 Apotex Technologies Inc. Liquid formulation for deferiprone with palatable taste
WO2010020959A1 (en) * 2008-08-21 2010-02-25 University Of Cape Town Resveratrol-containing composition for treating heart failure
WO2011000104A1 (en) 2009-07-03 2011-01-06 Apotex Technologies Inc. Fluorinated derivatives of 3-hydroxypyridin-4-ones
GB201005394D0 (en) * 2010-03-30 2010-05-12 Magnus Intellectual Property Ltd Therapy
US10478455B2 (en) 2010-03-30 2019-11-19 Ucl Business Ltd Therapeutic use of tetrathiomolybdate
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
WO2017168414A1 (en) * 2016-03-28 2017-10-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Iron chelators and combination thereof for the treatment of wolfram syndrome 2
MA51919A1 (en) 2018-05-04 2021-11-30 Orphalan Crystalline form of triethylenetetramine tetrachlorhydrate and corresponding pharmaceutical use
CN110746511B (en) * 2019-10-09 2021-05-28 安徽金太阳食品有限公司 Method for preparing modified starch for papermaking sizing agent from broken rice leftover in rice production

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147070A (en) * 1998-06-05 2000-11-14 Facchini; Francesco Methods and compositions for controlling iron stores to treat and cure disease states

Also Published As

Publication number Publication date
WO2003075910A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
AU2003222513A1 (en) Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
AU2003214725A1 (en) Preventing and/or treating cardiovascular disease and/or associated heart failure
AU2002331563A1 (en) Physiological heart pump control
ZA200108218B (en) Vascular surgery.
AU2003259537A1 (en) Blood glucose level control
ZA200200156B (en) Peptides that lower blood glucose levels.
AU2002336030A1 (en) Methods for preventing, treating or delaying cardiac toxicity using neuregulin
AU2003233437A1 (en) System for the diagnosis and monitoring of coronary artery disease, acute coronary syndromes, cardiomyopathy and other cardiac conditions
AU2002320610A1 (en) Tissue engineered heart valve
MXPA01012635A (en) Heart assist devices, systems and methods.
AU2001289640A1 (en) Intracardiac blood pump
PT1596868E (en) Method for treating severe heart failure and medicament therefor
AU2002367023A8 (en) Compositions and methods for treating heart failure
AU2003291536A1 (en) Method for the diagnosis and treatment of vascular disease
AU2002365057A8 (en) Compositions and methods for treating heart failure
EP1591113A4 (en) Blood pressure-lowering agent, vascular flexibility-improving agent and foods having these functions imparted thereto
AU6648200A (en) Method and composition for preventing or treating adverse physiological effects associated with cardiac disease
AU2003230552A1 (en) Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome
IS8356A (en) Medications, methods and dose control for the treatment and prevention of acute coronary heart disease
PT1487431E (en) Preventing and/or treating cardiovascular disease and/or associated heart failure
AU2003239445A1 (en) Medical clothing
WO2005115517A3 (en) Methods of treating diabetes
AUPS020602A0 (en) Treatment for heart failure
AU2003248679A1 (en) Treating disease using radium-225
AU2003294574A1 (en) Catheter loop manager

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase